I had heard from Joe that it would cost Generex $8.5 million to develop a COVID-19 Rapid Test. But obviously until the S1 is effective there’s no money to budget anything beyond their decision to focus on a vaccine. Joe has said he’s committed to not using any convertable notes since they are thieves, so besides the communications with the SEC they’ve been focusing on moving the vaccine forward. It makes sense though. Like all of us, Generex is hampered by the pandemic in multiple ways, the SEC is beyond their control, and obviously the team at GNBT needs to see success to eventually even get paid.